CONTENTS

· Faculty
· Scientific Agenda
· Continuing
  Medical Education
· Who Should Attend?
· Objectives
· Registration
· General Information
· Hotel   Accommodations
· Organizer

Ulrich Bogdahn, MD
University of Regensburg
Regensburg, Germany

Alba A. Brandes, MD
Bellaria-Maggiore Hospital
Bologna, Italy

Paul D. Brown, MD
Mayo Clinic
Rochester, Minnesota, United States

Arnab Chakravarti, MD
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts, United States

Olivier L. Chinot, MD
Hôpital de la Timone
Marseille, France

V. Peter Collins, MD, FRCP
University of Cambridge
Cambridge, United Kingdom

Andreas Jacobs, MD
University of Cologne
Cologne, Germany

Martin Klein, PhD
Vrije University Medical Center
Amsterdam, The Netherlands

Markus Klimek, MD, DEAA, EDIC
Erasmus University Medical Centre
Rotterdam, The Netherlands

Normand Laperriere, MD, FRCPC
Princess Margaret Hospital
Toronto, Ontario, Canada

Jan Jacob A. Mooij, MD, PhD
University Medical Centre Groningen
University of Groningen
Groningen, The Netherlands

Bart Neyns, MD, PhD
Academisch Ziekenhuis Vrije Universiteit Brussels
Brussels, Belgium

Antonio Omuro, MD
Groupe Hospitalier Pitié-Salpêtrière
Paris, France

Roy Rampling, PhD, FRCR, FRCP
Beatson Oncology Centre
Glasgow, United Kingdom

Michele Reni, MD
San Raffaele Scientific Institute
Milan, Italy

Uwe Schlegel, MD
University Hospital Bochum
Bochum, Germany

Edward G. Shaw, MD
Wake Forest University
Winston-Salem, North Carolina, United States

Susan C. Short, MD, PhD
University College London
London, United Kingdom

Riccardo Soffietti, MD
University of Torino
Torino, Italy

Luc Taillandier, MD, PhD
Centre Hospitalier Universitaire Nancy
Nancy, France

Hein te Riele, PhD
The Netherlands Cancer Institute
Amsterdam, The Netherlands

Patrizia Tunici, PhD
Siena Biotech
Siena, Italy

Martin J. van den Bent, MD, PhD
Erasmus University Medical Center
Rotterdam, The Netherlands

Charles J. Vecht, MD, PhD
Medical Center The Hague
The Hague, The Netherlands

Adam D. Waldman, PhD, MRCP, FRCR
Charing Cross Hospital
London, United Kingdom

Manfred Westphal, MD
University Hospital Hamburg-Eppendorf
Hamburg, Germany

Wolfgang Wick, MD
University of Heidelberg
Heidelberg, Germany

W.K. Alfred Yung, MD
MD Anderson Cancer Center
Houston, Texas, United States

Friday, 30 March 2007

8:30
Welcome and introduction

Session I: Diagnosis and prognosis

8:35
The role of combined PET/MRI in daily patient management
Andreas Jacobs, MD

9:00
Prognosis of patients with anaplastic oligodendroglial tumors with and without 1p/19q loss
Martin J. van den Bent, MD, PhD

9:20
The new WHO classification: Does classical pathological classification and grading still matter?
V. Peter Collins, MD, FRCP

9:40
Discussion

9:50
Coffee break

Session II: Low-grade gliomas
Moderator: Martin J. van den Bent, MD, PhD

10:10
The identification of malignant progression in adult low-grade gliomas with quantitative MRI
Adam D. Waldman, PhD, MRCP, FRCR

10:35
Prognostic factors and optimization of therapy: A French approach
Luc Taillandier, MD, PhD

11:00
Can we cure good prognosis low-grade glioma patients with extensive resections?
Edward G. Shaw, MD

11.25
Discussion

Session III: Parallel meet the professor breakout sessions

11:40
State-of-the-art: Chemotherapy
Martin J. van den Bent, MD, PhD

State-of-the-art: Radiotherapy
Roy Rampling, PhD, FRCR, FRCP

State-of-the-art: Targeted agents
W.K. Alfred Yung, MD

12:25
Lunch

Session IV: Primary CNS lymphoma
Moderator: Antonio Omuro, MD

13:25
Primary CNS lymphoma: Can we leave out intrathecal treatment?
Uwe Schlegel, MD

13:50
Primary CNS lymphoma: Salvage treatment after failure to HD-methotrexate
Michele Reni, MD

14:10
Delayed neurotoxicity: What is the experience and how to approach elderly patients?
Antonio Omuro, MD

14:35
Discussion

14:45
Coffee break

Session V: Other primary CNS tumors
Moderator: Susan C. Short, MD, PhD

15:10
Radiotherapy or chemotherapy for adult medulloblastoma?

Radiotherapy is the standard of care
Susan C. Short, MD, PhD

When chemotherapy should be used
Alba A. Brandes, MD

15:40
Is gliomatosis cerebri a separate entity which requires a different approach?
Olivier L. Chinot, MD

16:00
Radiotherapy in spinal cord tumors: Which ones and why?
Roy Rampling, PhD, FRCR, FRCP

16:20
Adult ependymoma: What is the optimal treatment strategy?
Riccardo Soffietti, MD

16:40
Discussion

17:00
Adjourn

Saturday, 31 March 2007

8:30
Welcome to day two

Session VI: High-grade gliomas
Moderator: W.K. Alfred Yung, MD

8:35
Overcoming MGMT mediated resistance in glioma: Current concepts
Olivier L. Chinot, MD

8:55
Underlying mechanisms of response to radiotherapy with temozolomide
Arnab Chakravarti, MD

9:20
Dose-dense temozolomide: Activity and management of toxicity
Bart Neyns, MD, PhD

9:45
Pseudoprogression in high-grade glioma after radiotherapy and temozolomide: Is it an issue?
Normand Laperriere, MD, FRCPC

10:10
Combining radiotherapy, temozolomide and enzastaurin
Wolfgang Wick, MD

10:35
Discussion

10.55
Coffee break

Session VII: Recent advances in surgical techniques
Moderator: Jan Jacob A. Mooij, MD, PhD

11:15
An update of convection-enhanced delivery strategies: Are we making progress?
Manfred Westphal, MD

11:35
The implementation of fluorescent guided surgery for high-grade gliomas
Jan Jacob A. Mooij, MD, PhD

11:55
Awake craniotomy: The anesthesist’s perspective
Markus Klimek, MD, DEAA, EDIC

12:15 Discussion

12:30 Lunch

Session VIII: Quality of life and research advances

13:30
The impact of extent of resection on quality of life
Paul D. Brown, MD

13:50
Seizure control
Charles J. Vecht, MD, PhD

14:10
The neurocognitive impact of delivering or withholding adjuvant whole brain radiotherapy
Paul D. Brown, MD

14:30
Long-term follow up of cognition in irradiated low-grade glioma patients
Martin Klein, PhD

14:50
Discussion

15:10
Coffee break

Session IX: Basic developments in glioma
Moderator: Manfred Westphal, MD

15:35
Antisense TGF strategy in glioma
Ulrich Bogdahn, MD

15:55
Targeting stem cells for the treatment of glioma: An update
Patrizia Tunici, PhD

16:20
New trials on angiogenesis inhibiting agents
W.K. Alfred Yung, MD

16:40
Resistance to chemotherapy: Mismatch and PARP
Hein te Riele, PhD

17:05
Chair summary and take home message

17:10
Adjourn

The Perspectives in Central Nervous System Malignancies 3 congress is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.”

The Perspectives in Central Nervous System Malignancies 3 congress is designated for a maximum of 12 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

This program is intended for neuro-oncologists, radiation oncologists, neurosurgeons, neurologists, pathologists and other healthcare administrators in active clinical practice involved and/or interested in CNS tumors and or secondary brain metastases. No specialized knowledge is required for participation other than basic familiarity with the principles of cancer biology and neurobiology.

After successful completion of this course, attendees should be able to:

• Comment on the newest trends in imaging and their role in monitoring progression of CNS malignancies
• Discuss state-of-the-art advancements in neurosurgery for CNS malignances
• Evaluate novel treatment strategies and newly approved agents for high-grade gliomas
• Describe the heterogeneity within these tumor types and the key factors to consider when developing individual patient treatment plans
• Identify expected outcomes and toxicities of standard therapies
• Recognize quality of life issues and incorporate them into management strategies
• Apply the most up to date therapies to a wide variety of CNS malignancies

REGISTRATION IS FULL

Regular .....................€349
If payment received by 22 March 2007

Full/Onsite: ...............€449
To register after 22 March 2007

To Register: REGISTRATION IS FULL. Registration confirmations will be issued before the Congress.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: To pre-register, registration and payment must be received no later than 22 March 2007. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at online to ensure program is being held as scheduled and to confirm that meeting is not full. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add €50 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the Congress: 278 Perspectives in Central Nervous System Malignancies III. An attendee is not registered until full payment is received.

Wire to: Bank of America, NA London, 1 Alie Street E1ADE London UK, Swift Code: BOFAGB22, Sort Code: 165050 Beneficiary: Bank of America Domestic Deposit #5687, Account #: 600895687029, Reference: Imedex, Inc. Account # 10726-118, IBAN: GB89 BOFA 1650 5095 6870 29.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, Congress materials, processing of certificates of attendance, and all event functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex no later than 22 March 2007. The amount of registration fees remitted, minus a €90 administrative charge, will be refunded after the Congress. Substitutions are accepted with written notification. No refunds will be made if notice is received after 22 March 2007.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event program content is subject to change without notice.

Congress Location and Registration
Sheraton Warsaw Hotel and Towers
ul. Boleslawa Prusa 2
00-493 Warsaw, Poland
Tel.: +48 22 450 6100
Fax: +48 22 450 6200
http://www.starwoodmeeting.com/StarGroupsWeb/res?id=0701094255&key=D44D3

The Registration and Information Desk will be staffed:
30 March 2007: 7:30 – 17:00
31 March 2007: 7:30 – 17:30

Discounted Airfares
Contact Congress travel agent, Age of Travel, for assistance with your travel needs. Age of Travel can also accommodate pre- and post-Congress extensions.
Tel.: +1 (800) 523 4954 or +1 (404) 591 7120
Email: imedex@ageoftravel.com

Italian Participants
Fargo International Meetings & Conventions SRL has been appointed as the official agency for government authorization for Italian participants. You may contact them directly at:
Fargo International Meetings & Conventions SRL
Via Piattro Maroncelli 44/66, 50137 Firenze, Italy
Tel.: +39 055 600 555
Fax: +39 055 609 078

Sheraton Warsaw Hotel and Towers
ul. Boleslawa Prusa 2
00-493 Warsaw, Poland
Tel.: +48 22 450 6100
Fax: +48 22 450 6200
http://www.starwoodmeeting.com/StarGroupsWeb/res?id=0701094255&key=D44D3

Why wait to visit Warsaw? The city boasts a wealth of history, the birthplace of Chopin, fantastic palaces, and of course the graceful elegance of the Sheraton Warsaw Hotel and Towers. Located in the heart of the city, Warsaw's finest luxury property is the first hotel on the historic Plac Trzech Krzyzy (Three Cross Square), which is close to the Polish Parliament, the diplomatic district, the enchanting Lazienki Park, and fabulous cafés and bars of Warsaw. A short stroll will bring you to the chic shopping boulevard of Nowy Swiat, which leads to the famous Old Town. This is Warsaw's UNESCO listed area, rebuilt from scratch after its wholesale destruction during World War II, now a thriving center of cultural significance.

The charm of the area outside sweeps into the hotel with its spacious and elegant guest rooms, its creative cuisine, its signature SomePlace Else bar where international bands set the tone, its fitness center, which was voted the best in Warsaw, its business center and a perfect gift shop.

"Witamy" - we welcome you to Sheraton Warsaw Hotel and Towers.

For the convenience of attendees, a limited number of rooms have been reserved until 1 March 2007 at a discounted rate of €120.00 single occupancy or €130.00 double occupancy. These rates include a breakfast buffet served in the Lalka Restaurant. This rate does not include VAT at 7%. This rate is not guaranteed outside the Congress dates or after 1 March 2007.

To reserve your room please visit the hotel's website at http://www.starwoodmeeting.com/StarGroupsWeb/res?id=0701094255&key=D44D3. To receive the group rate, reservations must be made on-line. Reservation requests received after 1 March 2007 may not be guaranteed the group rate.

          4325 Alexander Drive
          Alpharetta, GA 30022-3740 USA
          Tel.: +1 (770) 751 7332
          Fax: +1 (770) 751 7334
          Email: meetings@imedex.com
          Web: www.imedex.com